A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide

Antiviral Therapy

Volumn 11, Issue 3, 2006, Pages 315-319

  Beatty, George ^a,b   Hunt, Peter ^a,b   Smith, Anna ^a,b   Hoh, Rebecca ^a,b   Huang, Wei ^c   Martin, Jeff ^a,b   Deeks, Steven G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ENFUVIRTIDE; LOPINAVIR; RITONAVIR;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; GENOTYPE; HUMAN; IMMUNE RESPONSE; MULTIVARIATE ANALYSIS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDE FRAGMENTS; PILOT PROJECTS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 33744756034     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society, USA Panel. JAMA 2004; 292:251-265.
2. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137:381-433.
3. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
4. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
5. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16:201-207.
6. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14:2857-2867.
7. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
8. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-846.
9. Izopet J, Massip P, Souyris C, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 2000; 14:2247-2255.
10. Devereux HL, Emery VC, Johnson MA, et al. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 2001; 65:218-224.
11. Ruiz L, Ribera E, Bonjoch A, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the retrogene study. J Infect Dis 2003; 188:977-985.
12. Benson C, Downey G, Havlir DV, et al. A 16-week treatment interruption does not improve the virologic response to multidrug salvage therapy in treatment-experienced patients: 48-week results from ACTG A5086. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004. San Franciso, CA. Abstract 58.
13. Walmsley S, La Pierre N, Loutfy M, et al. CTN 164: A prospective randomized trial of structured treatment interruption vs immmediate switching in HIV-infected patients experiencing virologic failure on HAART. Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005. Boston, MA, USA. Abstract 580.
14. Deeks SG, Grant RM, Wrin T, et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 2003; 17:361-370.
15. Katlama C, Dominguez S, Gourlain K, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-226.
16. AIDSinfo [homepage on the Internet]. Panel on clinical practices for treatment of HIV infection convened by the department of health and human services (DHHS): Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [cited 28 April 2005]. Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf
17. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992-1000.